Healthy Skepticism Library

Items published during the years 2000 to 2009

There are 14385 items in the Healthy Skepticism Library that were published during the years 2000 to 2009.

Page 136 of 144 pages ‹ First  < 134 135 136 137 138 >  Last ›

HSL7661
Vidotti CC, Pereira DM, Marin NJ.
Drug nomenclature in Brazil: The official project "Harmonization of drug and excipients nomenclature for use in medicines"
International Pharmaceutical Federation World Congress 2002; 62:(147):

HSL7663
Bessell TL, Silagy CA, Anderson JN, Hiller JE, Sansom LN.
Can we regulate e-pharmacies?
International Pharmaceutical Federation World Congress 2002; 62:(68):

HSL7664
Subramaniam V, Schmid J.
Patient safety and regulatory initiatives through drug quality monitoring: Perspectives from the Food and Drug Administration
International Pharmaceutical Federation World Congress 2002; 62:(9):

HSL7666
Griffenhagen G.
150 years of American pharmacy
International Pharmaceutical Federation World Congress 2002; 62:(153):

HSL7668
Wogalter MS, Smith-jacksontl , Mills BJ, Paine CS.
The effects of print format in direct-to-consumer prescription drug advertisements on risk knowledge and preference
Drug Information Journal 2002; 36:(3):693-705

HSL7670
Kiene B, Braun N, Freund M, Kliegl T.
Public advertising for prescription medicine
Deutsche Apotheker Zeitung 2002; 142:(18):59-63

HSL7672
Sellers LJ.
Lilly marketers cross the line
Pharmaceutical Executive 2002; 22:(9):20

HSL7676
Kiene B, Braun N, Freund M, Kliegel T.
Public advertising for prescription medication. Part 2. Different interests and solutions
Deutsche Apotheker Zeitung 2002; 142:(19):47-50,55-57

HSL7677
Southern WA.
Sources of drug market data [1953].
Pharm Hist 2002; 44:(2):77-82

HSL7679
Houlton S.
Drug info war heats up
Pharmaceutical Executive 2002; 22:(8):30

HSL7730
Alonso J.
CRM - The 'ecosystem' difference
Pharmaceutical Executive 2002; 22:(8):44,46,48,50,52

HSL7732
O'Hara P.
Policing CRM sampling
Pharmaceutical Executive 2002; 22:(8):56,58,60,62-63,66

HSL7733
Wechsler J.
House adopts Medicare rx benefit
Pharmaceutical Executive 2002; 22:(8):26,28

HSL7734
Buckley B.
Center saves millions via indigent care plans
Pharmacy Practice News 2002; 29:(7):13, 51

HSL7735
Egler M, Geursen R.
Reference pricing: When hope triumphes over reality
Drugs Made in Germany 2002; 45:(2):35-38,40-42

HSL7736
Koo M, Krass I, Aslani P.
Consumer opinions on medicines information and factors affecting its use - an Australian experience
International Journal of Pharmacy Practice 2002; 10:(2):107-114

HSL7737
Drugs in 2001 - A number of ruses unveiled
Prescrire International 2002; 11:(58):58-60

HSL7738
Boland KA, Kennedy AG, Possidente CJ.
Development of an annual program to discuss innovative pharmacy practices in Vermont
ASHP Midyear Clinical Meeting 2002;

HSL7739
Peters BN, Boster EA, Kroskie CA, Morvay SI, Zaucha JA.
Redesign of a pharmacy internship program
ASHP Midyear Clinical Meeting 2002;

HSL7740
Del PAGGIO.
Evaluation of atypical antipsychotic medication assistance programs in a county mental health system
ASHP Midyear Clinical Meeting 2002;

HSL7741
Daberko JD, Bays AM, Kier KL.
Evaluating web-based direct-to-consumer advertising
ASHP Midyear Clinical Meeting 2002;

HSL7742
Rosier RA, Phillips RE, Elam JW.
Medication assistance outpatient program; providing access to free or low cost pharmaceuticals.
ASHP Midyear Clinical Meeting 2002;

HSL7743
Aggarwal K, Cowley EP.
Beyond approved labeling: The USPDI medication information development process.
ASHP Midyear Clinical Meeting 2002;

HSL7744
Top 10 drugs of 2001
Pharmacy Times 2002; 68:(4):10,12,15

HSL7745
Smith NV, Ramseyer KE.
Taking the package insert into the electronic age
Drug Information Journal 2002; 36:(2):429-434

HSL7746
Kaupp GS, Lynch SB.
To regain control of their drug costs, health plans must understand the road they've traveled
Drug Benefit Trends 2002; 14:(4):49-50

HSL7747
Advertised prescription drugs are the hot sellers
Drug Benefit Trends 2002; 14:(4):4

HSL7748
Chumney EC, Simpson KN.
The emerging role of the consumer in pharmaceutical pricing decisions
Disease Management and Health Outcomes 2002; 10:(4):229-232

HSL7749
Tieman J.
Drug-altered states - As pharmaceutical spending continues to soar, state legislatures are taking bold steps to rein in their costs
Modern Healthcare 2002; 32:(17):28-31

HSL7750
Schobben AF, Rademaker CM.
Awakening attention for a particular target group. Drug registrations for children
Pharmaceutisch Weekblad 2002; 137:(18):651-654

HSL7751
Milne CP.
The single controlled trial: Industry survey indicates that implementation is still a work in progress
Drug Information Journal 2002; 36:(2):291-302

HSL7752
Saunders B, Farine A, Kellerman J.
Caught in the crosshairs - Pharmaceutical pricing and sales & marketing practices
Pharmaceutical Executive 2002; 22:(4):50,52,54,56,58

HSL7753
Wechsler J.
Congress expands drug safety surveillance as part of bioterrorism bill
Formulary 2002; 37:(7):368-369

HSL7754
Shalo S.
The cyber six: ePharma's hot growth spots
Pharmaceutical Executive 2002; 22:(1):72-74,76,78

HSL7755
Nozar RA.
Education and promotion of generics might put the brakes on pharm costs
Managed Healthcare Executive 2002; 12:(2):36, 38

HSL7756
Gebhart F.
Still growing - Steady, not stellar, growth marked the pharmaceutical market last year
Drug Topics 2002; 146:(6):25-26,28,30

HSL7757
Wechsler J.
Price push forces plans to shift costs to consumers - MCOs implement multi-tier benefit to slow drug-spending growth, but future fiscal controls could limit access
Managed Healthcare Executive 2002; 12:(1):32-33

HSL7760
Rybicki AL.
Pharmacists fill a prescription for good health
Michigan Pharmacist 2002; 40:(1):38-39

HSL7761
Gebhart F.
Pharmacists welcome vouchers in place of drug samples
Drug Topics 2002; 146:(2):25-26

HSL7766
Thornton RA, Hamilton S, Helmeczi AW.
Effective utilization of manufacturer's indigent medication reimbursement programs and patient financial screening to reduce financial losses in an ambulatory pharmacy setting.
ASHP Summer Meeting 2002; 59:36

HSL10247
Mongin Bulewski C.
Drug Discovery Technology 2002: Keynote lectures: 4-9 August 2002, Boston, MA, USA
IDrugs 2002; 5:(9):900-901

HSL10369
Dexmethylphenidate - Novartis/Celgene: Focalin, D-MPH, D-methylphenidate hydrochloride, D-methylphenidate, dexmethylphenidate, dexmethylphenidate hydrochloride
Drugs in R and D 2002; 3:(4):279-282

HSL10433
Selegiline: a second look.
Six years later: too risky in Parkinson's disease 2002; 11:(60):108-111

HSL10436
Iloprost - A small benefit in severe Raynaud's phenomenon
Prescrire International 2002; 11:(58):63

HSL10474
Frasca V, Paladini L, Balestrieri A.
Prescription information leaflets: An expression of pharmaceutical care
Giornale Italiano di Farmacia Clinica 2002; 16:(4):207-209

HSL10486
Ou YJ.
A survey of pharmacists' recommendation in a unit dose drug distribution system
Chinese Pharmaceutical Journal 2002; 54:(6):449-455

HSL10526
Oreskovic S.
Pharmacoeconomics - Concepts, methods and controverses
Medicus 2002; 11:(1):27-36

HSL10528
De Joncheere K, Rietveld AH, Huttin C.
Experiences with generics
International Journal of Risk and Safety in Medicine 2002; 15:(1-2):101-109

HSL10538
McCloskey A.
The high price of prescription drugs and its impact on the elderly.
Care Manag J 2002 Spr; 3:(3):143-53

HSL10539
Kellogg FR.
Editorial
Care Management Journals 2002; 3:(3):112

HSL10540
Brown K.
The medication merry-go-round
Science 2002; 299:(5613):1646-1649

HSL10548
Hilli R, Groop T.
Generic Substitution - The proposed procedure for the presciption of pharmaceuticals in Finland
EPC--European Pharmaceutical Contractor 2002; 101-103

HSL10549
Schulman D, Wallis D, Hunsperger H.
Prescription drug Co-Promotion: 21st century dealmaking
EPC European Pharmaceutical Contractor 2002; 26-28

HSL10550
Coppin B.
A call to regulate the online sale of prescription drugs
EPC European Pharmaceutical Contractor 2002; 18-20

HSL10624
Tacco F, Taggiasco N, Broissand C.
Quality assurance in hospital pharmacies: Dispensation of thalidomide
Pharmacien Hospitalier 2002; 37:(151):219-226

HSL10627
Tam J.
Seeing red over drug price comparisons [1]
Canadian Pharmaceutical Journal 2002-2003; 135:(10):

HSL10632
Breggin PR.
Fluvoxamine as a cause of stimulation, mania, and aggression: A critical analysis of the FDA-approved label
Ethical Human Sciences and Services 2002; 4:(3):211-227

HSL10637
Drachenberg KJ, Proll S, Urban E, Woroniecki SR.
Short-term immunotherapy using an allergy vaccine adjuvanted with monophosphoryl lipid A: A post-marketing surveillance study
International Review of Allergology and Clinical Immunology. 2002; 8:(4):219-223

HSL10642
Spinosi P, Ciampoli R, Turchetti M.
Did any change occurr in the NSAIDs prescription following the marketing of selective COX-2 inhibitors?
Giornale Italiano di Farmacia Clinica 2002; 16:(3):138-142

HSL10643
Horn SD.
Unintended consequences of restricting drug access
Drug Benefit Trends 2002; 14:

HSL10650
Krymchantowski AV, Irikura S, Barbosa JS, Lysia R, Tavares C, Rocha N, Moreira PF.
Headache medications in drugstores of Brazil. Profiles of orientation, recommendation and sale carried out by unskilled employees with inadequate approaches
Revista Brasileira de Medicina 2002; 59:(10-11):705-710

HSL10651
Mason RG, Donaldson D.
Lessons to be learned: A case study approach Chinese herbal nephropathy and urothelial malignancy
Journal of The Royal Society for the Promotion of Health 2002; 122:(4):266-267

HSL10654
Gallagher RM.
Methadone and spinal stimulation: Old wine in new bottles
Pain Medicine 2002; 3:(4):293
http://www.blackwell-synergy.com/rd.asp?code=PME&vol=3&page=293&goto=abstract

HSL10655
Kanemori DS.
Future packaging image
American Pharmaceutical Outsourcing 2002; 3:(4):18-22

HSL10657
Something for everyone - Patients, health care professionals and industry
Pharmaceutical Journal 2002; 269:(7228):861

HSL10659
Noferi JF, Arling ER, Dillon RL.
Counterfeit drugs: A new paradigm for security
American Pharmaceutical Review 2002; 5:(4):37

HSL10660
Dwyer P.
Drug therapy and legal liability
Australian Journal of Forensic Sciences 2002; 34:(2):45-46

HSL10661
Striking-off for Viagra sale to journalist
Pharmaceutical Journal 2002; 269:(7227):829

HSL10664
Zeidler H, Kaltwasser JP, Leonard JP, Kohlmann T, Sigmund R, Degner F, Hettich M.
Prescription and tolerability of meloxicam in day-to-day practice: Postmarketing observational cohort study of 13,307 patients in germany
Journal of Clinical Rheumatology 2002; 8:(6):305-315

HSL10665
Patient packs need attention too
Pharmaceutical Journal 2002; 269:(7226):766

HSL10666
Wechsler J.
Major changes ahead for FDA
Pharmaceutical Technology Europe 2002; 14:(11):17-20

HSL10667
Albedo A.
Battle commences on the future of EU drugs
Pharmaceutical Technology Europe 2002; 14:(11):11-13

HSL10670
Sodium oxybate/GHB approved for cataplexy
WHO Drug Information 2002; 16:(2):136

HSL10671
Alosetron hydrochloride: Restricted marketing
WHO Drug Information 2002; 16:(2):135

HSL10672
MacKay DKJ.
Prescribing cascade for non-food-producing species, and changes relating to cushing's disease [1]
Veterinary Record 2002; 151:(21):643

HSL10673
Pet medicines 'resource pack' for pharmacists
Veterinary Record 2002; 151:(21):620

HSL10674
Abraham J.
Making regulation responsive to commercial interests: Streamlining drug industry watchdogs
British Medical Journal 2002; 325:(7373):1164-1167

HSL10675
Barnes J.
Herbal therapeutics: (7) Colds
Pharmaceutical Journal 2002; 269:(7224):716

HSL10676
OTC availability shout not be endorsed yet [1]
Pharmaceutical Journal 2002; 269:(7224):711

HSL10677
Cost and compliance affect statin use
Pharmaceutical Journal 2002; 269:(7224):706

HSL10678
Dispensing glucosamine
Pharmaceutical Journal 2002; 269:(7224):705

HSL10821
Curth L.
The commercialisation of medicine in the popular press: English almanacs 1640-1700.
Seventeenth Century 2002; 17:(1):48-69

HSL11900
Goldman CR, Cutler DL.
Pharmaceutical industry support of psychiatric research and education: Ethical issues and proposed remedies.
Backlar P, Cutler DL. Ethics in community mental health care: Commonplace concerns. New York: Kluwer Academic/Plenum Publishers 2002

HSL12352
Quintaneiro T.
[The Brazilian pharmaceutical market and the North American war effort].
Estud Hist. 2002; (29):141-64

HSL13290
Lexchin J, Mintzes B.
Direct-to-Consumer Advertising of Prescription Drugs: The Evidence Says No
Journal of Public Policy and Marketing 2002; 21:(2):194-201
http://web.archive.org/web/20080511145449/http://www.marketingpower.com/content18627.php

HSL13304
Pecotich A, Ward SP, Song Y.
Just a Spoonful of Sugar: Patent Brand Name Effects on the Antidepressant Prescription Habits of Psychiatrists and General Practitioners
Cadeaux J, Pecotich A, Eds . Macromarketing in the Asia Pacific Century: The Proceedings of the 27th Annual Macromarketing Conference Sydney: University of New South Wales 2002

HSL13370
Schubert F.
Health technology assessment. The pharmaceutical industry perspective
Int J Technol Assess Health Care. 2002 Spring; 18:(2):184-91
http://www.ncbi.nlm.nih.gov/pubmed/12053418

HSL16342
Healy D
The Creation of Psychopharmacology. Cambridge: Harvard University Press 2002
http://books.google.com.au/books?id=6O2rPJnyhj0C&dq=Healy,+David.+The+Creation+of+Psychopharmacology.&printsec=frontcover&source=bn&hl=en&ei=MJyYSti2EJjQ6gOa4ODnBA&sa=X&oi=book_result&ct=result&resnum=4#v=onepage&q=&f=false

HSL17904
Ed.
Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?
BMJ 2002; 324:(7349):1287
http://www.bmj.com/cgi/content/extract/324/7349/1287

HSL17985
Mavroforou A, Michalodimitrakis E
Legal aspects related to marketing and use of medicinal products in Greece.
Med Law. 2002; 21:(1):1-10
http://www.ncbi.nlm.nih.gov/pubmed/12017435

HSL19052
Schwartz LM, Woloshin S.
Marketing medicine to the public: a reader's guide.
JAMA 2002 13; 287:(6):774-5
http://jama.ama-assn.org/content/287/6/774.long

HSL19392
Azoulay P
Do pharmaceutical sales respond to scientific evidence?
J Econ Manage Str 2002; 11:551–594
http://ideas.repec.org/a/bla/jemstr/v11y2002i4p551-594.html

HSL2239
Schwab D.
Patent protection is at forefront of the pharmaceutical industry's concerns for the coming years
STAR-LEDGER 2001 Dec 30

HSL2240
Kolata G.
Questions Grow Over Usefulness of Some Routine Cancer Tests
New York Times 2001 Dec 30
http://www.nytimes.com/2001/12/30/us/questions-grow-over-usefulness-of-some-routine-cancer-tests.html?pagewanted=1

HSL2238
Freudenheim M, Petersen M.
The Drug-Price Express Runs Into a Wall
The New York Times 2001 Dec 23
http://www.nytimes.com/2001/12/23/business/the-drug-price-express-runs-into-a-wall.html?pagewanted=1

HSL17994
Somerset M, Weiss M, Fahey T.
Dramaturgical study of meetings between general practitioners and representatives of pharmaceutical companies; Commentary: dramaturgical model gives valuable insight.
BMJ 2001 Dec 22-29; 323:(7327):1481-4
http://www.bmj.com/cgi/content/full/323/7327/1481?view=long&pmid=11751364

HSL2236
Who Medicines Expert Calls For New Rules Against Commercial Bias In Medical Research
J Adv Nurs. 2001 Dec 17
http://www.ncbi.nlm.nih.gov/pubmed/12108409

HSL2237
Firn D.
Patent disputes and litigation take shine off 2001
Financial Times 2001 Dec 17

HSL17992
Zhan C, Sangl J, Bierman AS, Miller MR, Friedman B, Wickizer SW, Meyer GS.
Potentially inappropriate medication use in the community-dwelling elderly: findings from the 1996 Medical Expenditure Panel Survey.
JAMA 2001 Dec 12; 286:(22):2823-9
http://jama.ama-assn.org/cgi/content/full/286/22/2823

HSL17993
Avorn J.
Improving drug use in elderly patients: getting to the next level.
JAMA 2001 Dec 12; 286:(22):2866-8
http://jama.ama-assn.org/cgi/content/full/286/22/2866

Page 136 of 144 pages ‹ First  < 134 135 136 137 138 >  Last ›